Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Terbinafine-associated hepatotoxicity.

Challa Ajit1, Attaya Suvannasankha, Nayere Zaeri

  • 1Department of Internal Medicine, Lankenau Hospital, Wynnewood, Pennsylvania, USA.

The American Journal of the Medical Sciences
|June 7, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-Cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Bystander or perpetrator: Unravelling the significance and challenges of MGUS.

Blood reviews·2026
Same author

Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses.

Clinical lymphoma, myeloma & leukemia·2025
Same author

Diagnostic sequencing identifies high-risk markers and mechanisms of resistance to guide immunotherapy selection.

Blood advances·2025
Same author

Bispecific T-cell engagers for relapsed/refractory multiple myeloma after solid organ transplantation: A case series.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research·2025

Terbinafine, used for fungal infections, can cause liver damage. Monitoring liver function and early detection of abnormalities are crucial for patient safety during treatment.

Area of Science:

  • Dermatology
  • Hepatology
  • Clinical Pharmacology

Background:

  • Terbinafine is a widely used antifungal medication for dermatophytic infections.
  • While generally safe, rare cases of liver toxicity have been reported.

Observation:

  • A case of severe cholestatic hepatitis linked to terbinafine use is presented.
  • The patient responded to corticosteroids after initial treatment with ursodeoxycholic acid and cholestyramine.

Findings:

  • Literature review suggests potential risk factors for terbinafine-induced hepatotoxicity.
  • The metabolite 7,7-dimethylhept-2-ene-4-ynal (TBF-A) may contribute to liver injury.
  • Hepatotoxicity might involve mechanisms beyond idiosyncratic reactions.

Implications:

Related Experiment Videos

  • Clinical monitoring and periodic liver function tests are recommended for patients on terbinafine.
  • Prompt drug discontinuation and further evaluation are advised upon detecting abnormal liver function.